PRPH抗体

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: TM4 cell lysate, Primary antibody: P00622(PRPH Antibody) at dilution 1/200, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 9 minutes    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human cervical cancer tissue using P00622(PRPH Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P00622(PRPH Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

PRPH antibodies target peripherin, a type III intermediate filament protein primarily expressed in neurons of the peripheral nervous system (PNS) and subsets of central nervous system (CNS) neurons. Peripherin plays a structural role in maintaining neuronal integrity, axon outgrowth, and intracellular transport. Its dysregulation has been linked to neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and Charcot-Marie-Tooth neuropathy.

PRPH antibodies are of interest in both research and clinical contexts. In research, they serve as tools to study peripherin's function, localization, and interactions in neuronal health and disease. Clinically, anti-PRPH antibodies are occasionally detected in autoimmune neurological disorders, though their pathogenic role remains unclear. Some studies associate them with neuropathies or paraneoplastic syndromes, but their diagnostic specificity is limited.

Notably, peripherin exists in multiple splice variants, and PRPH antibodies may exhibit varying reactivity depending on isoforms. This complicates interpretations in disease models. Recent work explores peripherin aggregation in ALS, with PRPH antibodies aiding in detecting pathological inclusions. Challenges include distinguishing between antibodies generated experimentally and those arising spontaneously in autoimmune conditions. Further research is needed to clarify their clinical relevance and potential as biomarkers or therapeutic targets.